Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the  BEST-2 trial

K. Grimwood (Gold Coast (QLD), Australia)

Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment
Session: Bronchiectasis: new insights in diagnosis and treatment
Session type: Lunchtime session
Number: 4819
Disease area: Paediatric lung diseases

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Grimwood (Gold Coast (QLD), Australia). Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the  BEST-2 trial. International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Oral antibiotics vs placebo for exacerbations of paediatric bronchiectasis
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection
Year: 2019



Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results
Source: Eur Respir J 2012; 40: 17-27
Year: 2012



Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 544s
Year: 2002

A comparison of in-hospital and HITH-based treatment of respiratory exacerbations in children with bronchiectasis
Source: International Congress 2019 – Novel findings in paediatric respiratory infections
Year: 2019

Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors
Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD
Year: 2003


Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 566s
Year: 2003

Procalcitonin-guided antibiotic therapy in acute exacerbations of COPD (AECOPD): a randomised trial - The ProCOLD Study
Source: Eur Respir J 2005; 26: Suppl. 49, 464s
Year: 2005

Antibiotic treatment and prevention of exacerbations of COPD
Source: Eur Respir Monogr 2013; 60: 96-106
Year: 2013


Penetration of moxifloxacin in bronchial secretions in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Time-to-treatment failure in the Belgian randomized controlled trial with azithromycin for acute COPD exacerbations requiring hospitalization
Source: International Congress 2016 – Highlights in the management of COPD and beyond
Year: 2016


Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001

FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004)
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection
Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Year: 2009


The low dose macrolides for prevention of exacerbations in non-CF bronchiectasis
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015

Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
Source: Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020
Year: 2020



Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009